Clinicopathological and molecular features of uterine smooth muscle tumours in patients with Li‐Fraumeni syndrome
Histopathology · 2026
DOI: 10.1111/his.70201 ↗Kurz gefasst
Fachartikel in der Zeitschrift Histopathology, 2026. Verfasst von Lawrence H Lin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Brigham and Women's Hospital, Mass General Brigham Enterprise, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Li-Fraumeni Syndrome, Uterine Neoplasms, Smooth Muscle Tumor. Die Arbeit nennt 69 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Aims Li‐Fraumeni syndrome (LFS) is a cancer predisposition syndrome characterized by germline TP53 mutations and increased risk of various malignancies. While rare uterine leiomyosarcomas (LMS) have been reported, other uterine smooth muscle tumours (uSMT) have not been studied in this context. Methods and Results We describe clinicopathological features of uSMT from 10 LFS patients (four uSMT of uncertain malignant potential (STUMP), two leiomyomas with bizarre nuclei [LMBN] and four with only conventional leiomyomas [LM]) and next‐generation sequencing results of eight tumours. Among six p53‐aberrant tumours (four STUMPs, one LMBN, one LM) by immunohistochemistry (IHC), three STUMPs had biallelic TP53 inactivation and three uSMT (two STUMPs, one LMBN) had loss of fumarate hydratase (FH) by IHC with inactivating FH variants. One patient with a p53‐aberrant, FH‐deficient LMBN had a concurrent p53‐wild‐type, FH‐proficient LM with a novel ACTG2::BRAF fusion. Two STUMPs with TP53 biallelic inactivation and intact FH had additional alterations, one with LMS features, including chromosome instability, ATRX, and RB1 alterations; the other with del(22q), CYLD, and ELOC mutations. The remaining two sequenced LM showed MED12 alterations, one with del(22q). No recurrences were seen in nine patients with follow‐up and no LMS were diagnosed. Conclusion uSMTs exhibit a broad morphologic spectrum in LFS, and multiple molecular alterations may drive tumorigenesis, including MED12 , FH , TP53 , RB1 , ATRX , and a novel ACTG2::BRAF fusion. Although some may be incidental, uSMT in this setting appears enriched for atypical morphology, FH deficiency, and aberrant p53 expression, suggesting an interplay between p53 and FH pathways in tumorigenesis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Brigham and Women's Hospital, Mass General Brigham Enterprise, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Pathology, Massachusetts General Hospital, Mass General Brigham Enterprise, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
ORCID-Profile: Lawrence H Lin, Igor Odintsov, Emily A Towery, Bradley J Quade, Marisa R Nucci, Zehra Ordulu, David L Kolin
Zitieren
APA
Lin, L. H., Odintsov, I., Towery, E. A., Quade, B. J., Nucci, M. R., Ordulu, Z., & Kolin, D. L. (2026). Clinicopathological and molecular features of uterine smooth muscle tumours in patients with Li‐Fraumeni syndrome. Histopathology. https://doi.org/10.1111/his.70201
Vancouver
Lin LH, Odintsov I, Towery EA, Quade BJ, Nucci MR, Ordulu Z, et al. Clinicopathological and molecular features of uterine smooth muscle tumours in patients with Li‐Fraumeni syndrome. Histopathology. 2026. doi:10.1111/his.70201
BibTeX
@article{Lin2026,
author = {Lin, Lawrence H and Odintsov, Igor and Towery, Emily A and Quade, Bradley J and Nucci, Marisa R and Ordulu, Zehra and Kolin, David L},
title = {Clinicopathological and molecular features of uterine smooth muscle tumours in patients with Li‐Fraumeni syndrome},
journal = {Histopathology},
year = {2026},
doi = {10.1111/his.70201}
}
EUVIMED